NEW YORK (GenomeWeb) – Nanosphere said after the close of the market on Thursday that it is exploring potential strategic alternatives and has hired Jefferies as an advisor.

NEW YORK (GenomeWeb News) – Investment bank Jefferies today downgraded Myriad Genetics and Cepheid to Hold from Buy.

NEW YORK (GenomeWeb News) – Investment bank Jefferies today upgraded shares of Sequenom to Buy following a survey of US commercial payors that suggests the San Diego-based firm is gaining "meaningful traction" in getting coverage for its MaterniT21 Plus LDT test.

"CMS is the decision-maker here regarding fee schedule placement [of genetic tests] and we are pleased they are recognizing the importance … of having stakeholders provide input on the questions they've asked," said David Mongillo, vice president for policy and medical affairs at the American Clinical Laboratory Association.

The investment firm lowered revenue estimates and the share-price target for Nanosphere following the FDA's denial of the company's Plavix metabolism test.

CFO Roger Moody talked up Nanosphere's test for Plavix metabolism and other tests in the company's pipeline at the Jefferies Global Healthcare Conference.

Sequenom reiterated its plans to launch its T21 test by the end of the year as an LDT, while Agilent is looking to move into the top ranks as a life science instrument vendor.

Gen-Probe sees growth opportunities with its Panther platform and tests for STDs, trichomonas, HPV, and blood screening.


An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.